Elon Musk’s Neuralink is shifting into high gear for 2026 as the company’s co-founder touts changes to the brain-computer ...

Whether a brain cancer drug enters the body through a needle in the arm or swallowed by mouth, the blood-brain barrier stands as a formidable last obstacle on the therapy’s journey to its destination.

SynuSight Biotech has licensed 18 F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment . SHANGH ...

EQS-News: BRAIN Biotech AG / Key word(s): Half Year Results/Half Year Report BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets 28.05.2024 / 07:30 ...

KeifeRx, announced that Chief Executive Officer Chris Hoyt will be speaking at two leading investor events during J.P. Morgan Healthcare Conference week. WASHINGTON, DC, UNITED STATES, January 5, 2026 ...

When it comes to treating cancer, the world has come a long way. However, there’s one particular cancer that even world-renowned physicians struggle to treat: brain cancer. That’s because the ...

Many people think of a cure for cancer as a single medical breakthrough, but in all likelihood, it will be a combination of medical and biotech innovations. NeOnc, Inc — a biotech company headed by ...

Antisense oligonucleotides (ASOs), which bind to RNA and prevent them from being translated into proteins, have gained popularity in recent years as a way to treat neurodegenerative diseases. However, ...

Gene therapy ‘switch’ may offer non-addictive pain relief. New approach targets pain signals while leaving the rest of the brain untouched.

EQS-Ad-hoc: BRAIN Biotech AG / Key word(s): Contract BRAIN Biotech AG signs exclusive pharma licensing agreement for G-dase E® CRISPR-Cas technology with Akribion Therapeutics GmbH for up to EUR 92.3 ...